Jim Robin­son takes over the reins at Urovant; Car­los Cam­poy moves to Cy­tomX

→ Af­ter near­ly a year as pres­i­dent and COO at Paragon Bio­sciences, Jim Robin­son has jumped to Urovant Sci­ences, where he will be pres­i­dent and CEO of the urol­o­gy-fo­cused biotech, suc­ceed­ing found­ing CEO Kei­th Katkin. Robin­son will con­tin­ue as a mem­ber of Urovant’s board of di­rec­tors. His pre­vi­ous stops in­clude Alk­er­mes as pres­i­dent and COO and a num­ber of po­si­tions at Astel­las and Scher­ing-Plough Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER